Advanced Therapies: Replacing the Missing Hormone

For many years, the only way to treat autoimmune hypoparathyroidism was to “mimic” the effects of the missing hormone using high doses of calcium and vitamin D. While conventional therapy is appropriate for many people, it does not address the underlying cause: the lack of Parathyroid Hormone (PTH).

Today, advanced therapies are available that replace the missing hormone itself, offering a more physiological approach for patients whose disease is difficult to control ^[1][2].

When Conventional Therapy Isn’t Enough

International guidelines recommend starting with conventional therapy, but they acknowledge that this approach may fail to provide adequate control for some patients ^[3][1]. Your doctor may consider switching you to PTH replacement if you experience ^[4][1]:

• Poor Quality of Life: Persistent fatigue or muscle symptoms despite stable blood levels ^[5].
• Renal Complications: High levels of calcium in the urine (hypercalciuria), frequent kidney stones, or declining kidney function (eGFR) ^[6].
• Unstable Calcium: Frequent episodes of dangerously low or high calcium that require emergency care ^[4].
• High Pill Burden: Needing to take such large amounts of calcium and vitamin D that it becomes unmanageable or causes severe digestive distress ^[7].

Palopegteriparatide (Yorvipath)

Palopegteriparatide (brand name Yorvipath, formerly TransCon PTH) is an approved option for adults with chronic hypoparathyroidism in regions such as the United States (FDA) and Europe (EMA) ^[2][8]. This medication is a “prodrug” designed to release PTH at a steady rate throughout the day ^[9].

Findings from the PaTHway clinical trial demonstrated significant benefits for many patients. At 26 weeks, approximately 79% of treated participants met the composite endpoint of achieving normal serum calcium, becoming independent from conventional active vitamin D, and requiring a vastly reduced dose of regular calcium ^[5]. The treatment also lowered mean 24-hour urine calcium levels ^[6][10]. Patients reported clinically meaningful improvements in physical functioning and overall quality of life ^[11]. While these lower urinary calcium levels are an important marker, long-term trials are still studying whether this prevents kidney stones or chronic kidney disease over decades.

Not everyone becomes completely supplement-independent on Yorvipath; some patients still need low doses of calcium or vitamin D.

The End of the Natpara Era

You may encounter older information about a drug called Natpara (rhPTH 1-84). While it was the first PTH replacement approved in 2015, global production of Natpara ceased in 2024 ^[12]. Due to long-standing manufacturing and delivery-device issues, it is no longer available for new or existing patients ^[13][14]. Patients previously taking Natpara should transition to alternative therapies under close supervision, following local jurisdiction and manufacturer guidelines ^[15].

Other PTH Options

While Yorvipath is the current approved specific therapy in many areas, other forms of PTH may be used:

• Teriparatide (PTH 1-34): Originally approved for osteoporosis (brand name Forteo), this is sometimes used “off-label” for hypoparathyroidism ^[9]. Because it has a very short half-life, it often requires multiple injections per day or the use of an insulin pump under strict specialist oversight ^[16]. It should never be substituted or obtained without expert supervision.

Safety and the Transition Process

Hormone replacement offers benefits but comes with rigorous requirements:

• Titration and Monitoring: Transitioning to Yorvipath requires a commitment to daily injections and frequent lab monitoring, especially during the first month as your doses are “titrated” (carefully adjusted) ^[15][17]. You must never abruptly stop calcium or calcitriol on your own.
• Adverse Effects: PTH replacement can cause calcium disturbances (both hypo- and hypercalcemia), orthostatic symptoms (dizziness when standing), and injection site reactions. There may also be specific label precautions for people with certain bone risks or cancer histories.

For many, shifting to hormone replacement can greatly reduce their reliance on supplements and improve control, but it requires a careful discussion of risks and benefits with an experienced endocrinologist.